The time course and significance of cannabis withdrawal
- PMID: 12943018
- DOI: 10.1037/0021-843x.112.3.393
The time course and significance of cannabis withdrawal
Abstract
Withdrawal symptoms following cessation of heavy cannabis (marijuana) use have been reported, yet their time course and clinical importance have not been established. A 50-day outpatient study assessed 18 marijuana users during a 5-day smoking-as-usual phase followed by a 45-day abstinence phase. Parallel assessment of 12 ex-users was obtained. A withdrawal pattern was observed for aggression, anger, anxiety, decreased appetite, decreased body weight, irritability, restlessness, shakiness, sleep problems, and stomach pain. Onset typically occurred between Days 1-3, peak effects between Days 2-6, and most effects lasted 4-14 days. The magnitude and time course of these effects appeared comparable to tobacco and other withdrawal syndromes. These effects likely contribute to the development of dependence and difficulty stopping use. Criteria for cannabis withdrawal are proposed.
Similar articles
-
Marijuana abstinence effects in marijuana smokers maintained in their home environment.Arch Gen Psychiatry. 2001 Oct;58(10):917-24. doi: 10.1001/archpsyc.58.10.917. Arch Gen Psychiatry. 2001. PMID: 11576029 Clinical Trial.
-
[Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence].Encephale. 2011 Sep;37(4):266-72. doi: 10.1016/j.encep.2010.12.007. Epub 2011 Feb 5. Encephale. 2011. PMID: 21981886 French.
-
Marijuana withdrawal in humans: effects of oral THC or divalproex.Neuropsychopharmacology. 2004 Jan;29(1):158-70. doi: 10.1038/sj.npp.1300310. Neuropsychopharmacology. 2004. PMID: 14560320 Clinical Trial.
-
Clinical management of cannabis withdrawal.Addiction. 2022 Jul;117(7):2075-2095. doi: 10.1111/add.15743. Epub 2022 Jan 10. Addiction. 2022. PMID: 34791767 Free PMC article. Review.
-
The marijuana withdrawal syndrome: diagnosis and treatment.Curr Psychiatry Rep. 2005 Oct;7(5):360-6. doi: 10.1007/s11920-005-0036-1. Curr Psychiatry Rep. 2005. PMID: 16216154 Review.
Cited by
-
Advancing the science on cannabis concentrates and behavioural health.Drug Alcohol Rev. 2021 Sep;40(6):900-913. doi: 10.1111/dar.13281. Epub 2021 Mar 30. Drug Alcohol Rev. 2021. PMID: 33783029 Free PMC article. Review.
-
A comparison of cognitive behavioral therapy for insomnia to standard of care in an outpatient substance use disorder clinic embedded within a therapeutic community: a RE-AIM framework evaluation.Trials. 2022 Nov 28;23(1):965. doi: 10.1186/s13063-022-06885-7. Trials. 2022. PMID: 36443869 Free PMC article. Clinical Trial.
-
WHY NOT POT?: A Review of the Brain-based Risks of Cannabis.Innov Clin Neurosci. 2016 Apr 1;13(3-4):13-22. eCollection 2016 Mar-Apr. Innov Clin Neurosci. 2016. PMID: 27354924 Free PMC article. Review.
-
A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.Addict Biol. 2013 Nov;18(6):993-1002. doi: 10.1111/j.1369-1600.2012.00461.x. Epub 2012 Jun 28. Addict Biol. 2013. PMID: 22741619 Free PMC article. Clinical Trial.
-
Cannabis use during a voluntary quit attempt: an analysis from ecological momentary assessment.Drug Alcohol Depend. 2013 Oct 1;132(3):610-6. doi: 10.1016/j.drugalcdep.2013.04.013. Epub 2013 May 7. Drug Alcohol Depend. 2013. PMID: 23664121 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
